FLT3 and acute myeloid leukemia: Based on current data and ELN 2017 and 2022 recommendations, the CLSG/GCEL panel recommends that FLT3 mutation test results for all newly diagnosed and R/R AML patients be available in electronic patient records within 2–5 calendar days.